



NX-5948 Expanded Access Policy

At this time, enrollment in a clinical trial is the only method through which access to Nurix's investigational drug, NX-5948, is provided prior to its potential approval by applicable regulatory authorities and subsequent commercial availability. Our clinical trials have been designed to help demonstrate that our investigational drug will meet the safety and efficacy standards required for approval by applicable regulatory authorities, such as the U.S. Food and Drug Administration, and therefore represent the best and safest access for patients.

We understand that there are seriously ill patients who will not be eligible for our clinical trials and may not have options for alternative therapies, including investigational therapies in trials being conducted by other sponsors.

We will continue to evaluate the possibility of expanded access as we advance development of our investigational medicines. Certain requirements will need to be met prior to providing expanded access including the investigational drug is in active clinical development with sufficient data available to determine an appropriate dose and schedule for the patient's specific condition. If and when expanded access is provided, we will include the general criteria that will be used to evaluate and respond to such requests at that time. As authorized by the 21st Century Cures Act, Nurix may revise this posted expanded access policy at any time.

The availability of this policy or any revised version shall not serve as a guarantee of access to NX-5948 or any other investigational medicines by any individual patient.

Please visit <https://clinicaltrials.gov> for more information about current Nurix clinical trials.